WASHINGTON (dpa-AFX) - Ligand Pharmaceuticals Inc. (LGND) partner Viking
Therapeutics Inc. (VKTX) announced that it has priced its initial public
offering of 3 million shares of its common stock at an initial offering price to
the public of $8.00...
Ronald Evans, the heavyweight Salk Institute researcher and serial entrepreneur who co-founded Ligand Pharmaceuticals, Syndax, and X-Ceptor, is putting his shoulder behind a new stealth biotech in San Diego named Metacrine.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner TG Therapeutics,
Inc. (NASDAQ: TGTX) today announced the first presentation of preclinical data
demonstrating single agent and combination activity of two of TG Therapeutics'
CRT Capital initiated coverage on Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) with a Buy rating.
The target price for Ligand Pharmaceuticals is set to $102.
Ligand Pharmaceuticals shares have dropped 13.54% over the past 52 weeks, while...
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. TheStreet Ratings quantitative algorithm...
Ligand Pharmaceuticals Inc. (NASDAQ: LGND) reported in-line earnings for the fourth quarter.
The La Jolla, California-based company posted a quarterly profit of $7.1 million, or $0.34 per share, versus $1.9 million, or $0.09 per share, in the...
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Ligand Pharmaceuticals (LGND):